Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.ZIOP · Entity 8339 | Director | December 31, 2019 | January 03, 2020 |
| Atai Beckley N.V.ATAI · Entity 72536 | Director | November 04, 2025 | November 07, 2025 |
| Caribou Biosciences, Inc.CRBU · Entity 6445 | Director | February 20, 2026 | February 20, 2026 |
| Esperion Therapeutics, Inc.ESPR · Entity 30796 | Director | May 29, 2019 | May 31, 2019 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Chief Operating Officer | January 03, 2018 | January 06, 2018 |
| Protara Therapeutics, Inc.TARA · Entity 6203 | Director | June 09, 2020 | June 11, 2020 |
| TREVENA INCTRVN · Entity 85383 | Director | June 13, 2024 | June 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date December 31, 2019 · Filed January 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,780 |
Reported balance
After 2019-12-31 transaction · row 1
1 source rowRow 1 · 2019-12-31 · Grant · Acquired 31,780 · Balance 31,780 F1: 31,780 shares vest on 12/31/2020. |
Filing footnotes · ownership attribution and instrument terms
F1: 31,780 shares vest on 12/31/2020.
Atai Beckley N.V.
Report date November 04, 2025 · Filed November 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.28 · Expires 2035-11-04 | Direct | 56,818 |
Reported balance
After 2025-11-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-04 · Grant · Acquired 56,818 · Balance 56,818 F1: The stock option shall vest as to 100% of the underlying shares on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest as to 100% of the underlying shares on the first anniversary of the grant date.
Caribou Biosciences, Inc.
Report date February 20, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2036-02-19 | Direct | 45,000 |
Reported balance
After 2026-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-20 · Grant · Acquired 45,000 · Balance 45,000 F1: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.
Esperion Therapeutics, Inc.
Report date May 29, 2019 · Filed May 31, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,019 |
Reported balance
After 2019-05-29 transaction · row 1
1 source rowRow 1 · 2019-05-29 · Grant · Acquired 4,967 · Balance 5,019 F1: The shares vest in full on the earlier of (i) May 29, 2020 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest in full on the earlier of (i) May 29, 2020 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2019.
Pacira BioSciences, Inc.
Report date January 03, 2018 · Filed January 06, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.35 · Expires 2028-01-03 | Direct | 60,000 |
Reported balance
After 2018-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-03 · Grant · Acquired 60,000 · Balance 60,000 F1: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
Protara Therapeutics, Inc.
Report date June 09, 2020 · Filed June 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.00 · Expires 2030-06-08 | Direct | 9,000 |
Reported balance
After 2020-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-09 · Grant · Acquired 9,000 · Balance 9,000 F1: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
TREVENA INC
Report date June 13, 2024 · Filed June 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 · Expires 2034-06-13 | Direct | 13,700 |
Reported balance
After 2024-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-13 · Grant · Acquired 13,700 · Balance 13,700 F1: The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AtaiBeckley Inc.
Report date September 11, 2026 · Filed September 11, 2026
Section 16 reporting ended · disclosed 2026-09-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2034-06-13 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-11 · Disposition to issuer · Disposed 206,000 · Balance 0 F2: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2035-06-26 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-11 · Disposition to issuer · Disposed 103,000 · Balance 0 F2: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.28 · Expires 2035-11-04 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-11 · Disposition to issuer · Disposed 56,818 · Balance 0 F2: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2036-06-04 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-11 · Disposition to issuer · Disposed 208,063 · Balance 0 F2: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.
F2: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
CONSTELLATION PHARMACEUTICALS INC
Report date July 15, 2021 · Filed July 19, 2021
Section 16 reporting ended · disclosed 2021-07-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.57 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.81 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-15 · Disposition to issuer · Disposed 26,342 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.52 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
MARINUS PHARMACEUTICALS, INC.
Report date August 14, 2024 · Filed February 11, 2025
Section 16 reporting ended · disclosed 2025-02-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-11 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-08-14 · Purchase · Acquired 5,933 · Balance 304,600 F1: This purchase of the Issuer's common stock (the "Common Stock") on August 14, 2024 resulted in unintentional matching transactions for Section 16(b) reporting purposes. As a result, the Reporting Person has voluntarily paid to the Issuer $52,582.55 prior to the filing of this Form 4, representing the full amount of the profit realized in connection with the matching transactions less expenses, calculated in accordance with Section 16(b). The purchase of Common Stock on August 14, 2024 was matched against the Reporting Person's sale of Common Stock on February 16, 2024 pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units. F2: The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.09 to $1.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 2 · 2025-02-07 · Disposition to issuer · Disposed 125,064 · Balance 179,536 F3: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Common Stock held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. Row 3 · 2025-02-11 · Disposition to issuer · Disposed 179,536 · Balance 0 F3: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Common Stock held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. F4: Represents 179,536 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2034-06-18 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-11 · Disposition to issuer · Disposed 167,825 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.74 · Expires 2034-01-18 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-02-11 · Disposition to issuer · Disposed 335,650 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.94 · Expires 2033-01-26 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-02-11 · Disposition to issuer · Disposed 360,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.40 · Expires 2032-02-04 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-02-11 · Disposition to issuer · Disposed 193,050 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.60 · Expires 2031-01-15 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-02-11 · Disposition to issuer · Disposed 290,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.28 · Expires 2030-01-08 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-02-11 · Disposition to issuer · Disposed 450,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.28 · Expires 2029-08-06 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-02-11 · Disposition to issuer · Disposed 200,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.84 · Expires 2029-02-26 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-02-11 · Disposition to issuer · Disposed 15,917 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.76 · Expires 2028-09-19 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2025-02-11 · Disposition to issuer · Disposed 7,500 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This purchase of the Issuer's common stock (the "Common Stock") on August 14, 2024 resulted in unintentional matching transactions for Section 16(b) reporting purposes. As a result, the Reporting Person has voluntarily paid to the Issuer $52,582.55 prior to the filing of this Form 4, representing the full amount of the profit realized in connection with the matching transactions less expenses, calculated in accordance with Section 16(b). The purchase of Common Stock on August 14, 2024 was matched against the Reporting Person's sale of Common Stock on February 16, 2024 pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units.
F2: The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.09 to $1.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Common Stock held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash.
F4: Represents 179,536 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof.
RAPT Therapeutics, Inc.
Report date March 03, 2026 · Filed March 05, 2026
Section 16 reporting ended · disclosed 2026-03-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-03-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-03 · Other · Disposed 4,956 · Balance 0 F1: Represents the annual grant of restricted stock units ("RSUs") under the Issuer's Amended & Restated Non-Employee Director Compensation Policy, previously granted to the Reporting Person and reported on Form 4 dated February 2, 2026, which were scheduled to fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting. F2: The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the "Merger Agreement") with GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F3: Pursuant to the Merger Agreement, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the total number of Shares issuable in settlement of such RSU immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, which amount shall be paid in accordance with the Merger Agreement. F4: This Form 4 reports securities transacted pursuant to the Merger Agreement. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.44 | Direct | 0 |
Reported balance
After 2026-03-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-03 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the "Merger Agreement") with GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4: This Form 4 reports securities transacted pursuant to the Merger Agreement. F5: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the annual grant of restricted stock units ("RSUs") under the Issuer's Amended & Restated Non-Employee Director Compensation Policy, previously granted to the Reporting Person and reported on Form 4 dated February 2, 2026, which were scheduled to fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting.
F2: The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the "Merger Agreement") with GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").
F3: Pursuant to the Merger Agreement, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the total number of Shares issuable in settlement of such RSU immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, which amount shall be paid in accordance with the Merger Agreement.
F4: This Form 4 reports securities transacted pursuant to the Merger Agreement.
F5: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2021 Filed Jul 19, 2021 21:33 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,171 | Not disclosed Strike: $33.57 | Not disclosed |
DisclosureSEC source: 0001562180-21-004980 · primarydocument.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,171 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:47 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Option (Right to Buy) · Derivative | 13,171 | $0.00 Strike: $33.57 | $0.00 |
DisclosureSEC source: 0001562180-21-004077 · primarydocument.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,171 Underlying: Common Stock · 13,171 shares Expires 2031-06-01 F1 · derivative.exercise_date: This option was granted on June 2, 2021, and the shares underlying the option vest in equal quarterly installments through June 2, 2022, subject to continued service. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 21:02 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 68,577 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001429560-21-000007 · edgar.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,577 Underlying: Common Stock · 68,577 shares Expires 2031-05-28 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 01:14 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock option (right to buy) · Derivative | 290,000 | $0.00 Strike: $12.60 | $0.00 |
DisclosureSEC source: 0001104659-21-005523 · tm213599-7_4seq1.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 Underlying: Common Stock · 290,000 shares Expires 2031-01-15 F1 · derivative.exercise_date: Options to purchase shares of common stock vest in 36 equal monthly installments, commencing on 1/31/21. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:33 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $35.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035846 · doc4.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-06-08 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 22:13 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Options (Right to buy) · Derivative | 13,171 | $0.00 Strike: $37.52 | $0.00 |
DisclosureSEC source: 0001562180-20-004331 · primarydocument.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,171 Underlying: Common Stock · 13,171 shares Expires 2030-06-04 F1 · derivative.exercise_date: This option was granted on June 4, 2020, and the shares underlying the option vest in equal quarterly installments through June 4, 2021, subject to continued service. Read SEC document |
| May 13, 2020 Filed May 15, 2020 21:15 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 64,103 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001209191-20-029765 · doc4.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,103 Underlying: Common Stock · 64,103 shares Expires 2030-05-13 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 00:22 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 26,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-003243 · doc4.xml · nonDerivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,500 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. 3/24th of the shares were vested upon grant and 1/24th of the shares vest monthly thereafter, beginning on February 10, 2020. Settlement for the RSUs is deferred until the earliest to occur of (i) the Reporting Person's termination of service, (ii) death, (iii) disability and (iv) a change in control of the Issuer. In the event of a change in control of the Issuer, the RSUs will vest in full. Read SEC document |
| January 09, 2020 Filed Jan 14, 2020 00:22 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 15,737 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-003243 · doc4.xml · derivative · entry 6 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,737 Underlying: Common Stock · 15,737 shares Expires 2029-04-28 F2 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F10 · price: Received in the Merger in exchange for a stock option to acquire 82,500 shares of ArTara Sub common stock for $1.75 per share. F9 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly following April 29, 2019, for so long as the Reporting Person provides continuous service to the Issuer. Read SEC document |
| January 09, 2020 Filed Jan 14, 2020 00:22 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 6,676 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-003243 · doc4.xml · derivative · entry 5 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,676 Underlying: Common Stock · 6,676 shares Expires 2028-12-31 F2 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F8 · price: Received in the Merger in exchange for a stock option to acquire 35,000 shares of ArTara Sub common stock for $1.75 per share. F7 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly following January 1, 2019, for so long as the Reporting Person provides continuous service to the Issuer. Read SEC document |
| January 09, 2020 Filed Jan 14, 2020 00:22 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 9,537 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-003243 · doc4.xml · derivative · entry 4 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,537 Underlying: Common Stock · 9,537 shares Expires 2028-12-31 F2 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F4 · price: Received in the Merger in exchange for a stock option to acquire 50,000 shares of ArTara Sub common stock for $1.75 per share. F7 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly following January 1, 2019, for so long as the Reporting Person provides continuous service to the Issuer. Read SEC document |
| January 09, 2020 Filed Jan 14, 2020 00:22 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 2,861 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-003243 · doc4.xml · derivative · entry 3 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,861 Underlying: Common Stock · 2,861 shares Expires 2028-07-11 F2 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F6 · price: Received in the Merger in exchange for a stock option to acquire 15,000 shares of ArTara Sub common stock for $1.75 per share. F5 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly following August 1, 2018, for so long as the Reporting Person provides continuous service to the Issuer. Read SEC document |
| January 09, 2020 Filed Jan 14, 2020 00:22 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 9,537 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-003243 · doc4.xml · derivative · entry 2 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,537 Underlying: Common Stock · 9,537 shares Expires 2028-05-24 F2 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F4 · price: Received in the Merger in exchange for a stock option to acquire 50,000 shares of ArTara Sub common stock for $1.75 per share. F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly following June 1, 2018, for so long as the Reporting Person provides continuous service to the Issuer. Read SEC document |
| January 09, 2020 Filed Jun 11, 2020 17:32 UTC Amendment | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 15,641 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-035845 · doc4a.xml · derivative · entry 3 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,641 Underlying: Common Stock · 15,641 shares Expires 2029-04-28 F1 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F8 · price: Received in the Merger in exchange for a stock option to acquire 82,000 shares of ArTara Sub common stock for $1.75 per share. F7 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly following April 29, 2019, for so long as the Reporting Person provides continuous service to the Issuer. Read SEC document |
| January 09, 2020 Filed Jun 11, 2020 17:32 UTC Amendment | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 16,214 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-035845 · doc4a.xml · derivative · entry 2 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,214 Underlying: Common Stock · 16,214 shares Expires 2028-12-03 F1 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F5 · price: Received in the Merger in exchange for a stock option to acquire 85,000 shares of ArTara Sub common stock for $1.75 per share. F4 · derivative.exercise_date: The Option Shares shall vest in forty eight (48) approximately equal increments of three hundred thirty seven (337) whole Option Shares beginning on the first day of the first calendar month following December 4, 2018, and then on the first day of each of the next forty seven (47) months thereafter (each a "Vesting Date"), if Reporting Person has remained continuously engaged by the Issuer or any Affiliate through such Vesting Date; provided that, on the last such Vesting Date (being December 1, 2022), all of the Option Shares which had not vested by then will vest and become exercisable. F6 · balance_after: The Stock Options originally noted on Table II of the Reporting Person's Form 4 filed on 1/13/2020, in the amounts of 9,537 shares and 6,676 shares, respectively, with the expiration date of 12/31/2028, have been combined and reported hereto as one Stock Option, pursuant to the Board's approval on 12/04/2018. Read SEC document |
| January 09, 2020 Filed Jun 11, 2020 17:32 UTC Amendment | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 2,861 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-035845 · doc4a.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,861 Underlying: Common Stock · 2,861 shares Expires 2028-07-11 F1 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F3 · price: Received in the Merger in exchange for a stock option to acquire 15,000 shares of ArTara Sub common stock for $1.75 per share. F2 · derivative.exercise_date: One hundred nineteen (119) of the Option Shares shall vest as of the date of the grant, and the remaining Option Shares shall vest in forty six (46) approximately equal increments of fifty nine (59) whole Option Shares beginning on the first day of the first calendar month following the Date of Grant and then on the first day of each of the next forty five (45) months thereafter (each a "Vesting Date"), if the Reporting Person has remained continuously engaged by the Issuer or any Affiliate through such Vesting Date; provided that, on the last such Vesting Date (being May 1, 2022), all of the Option Shares which had not vested by then (being not less than 64 Option Shares) will vest and become exercisable, and that the vesting of all then unvested Option Shares shall be accelerated upon a Change of Control. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:54 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock option (right to buy) · Derivative | 1,800,000 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001104659-20-003102 · a4.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800,000 Underlying: Common Stock · 1,800,000 shares Expires 2030-01-08 F1 · derivative.exercise_date: Options to purchase shares of common stock vest in 36 equal monthly installments, commencing on 1/31/20. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:03 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 31,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-001165 · doc4.xml · nonDerivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,780 F1 · shares: 31,780 shares vest on 12/31/2020. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 21:08 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | PurchaseCommon stock | 100,000 | $1.25 | $125,000.00 |
DisclosureSEC source: 0001104659-19-072572 · a4.xml · nonDerivative · entry 1 Braunstein Scott · CIK 0001643875 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 20:33 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001104659-19-044912 · a4.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2029-08-06 F1 · derivative.exercise_date: Options to purchase shares of common stock vest in 48 equal monthly installments, commencing on 9/6/19. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:52 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 4,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-006919 · edgar.xml · nonDerivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,019 F1 · shares: The shares vest in full on the earlier of (i) May 29, 2020 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2019. Read SEC document |
| May 16, 2019 Filed May 16, 2019 21:29 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001209191-19-030516 · doc4.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 23:58 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock option (right to buy) · Derivative | 240,000 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001104659-19-011636 · a4.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2029-02-26 F1 · derivative.exercise_date: Options to purchase shares of common stock vest in 24 equal monthly installments of 10,000 shares each, commencing on 2/26/19 and continuing until the Reporting Person is terminated under the terms of the Reporting Person's employment agreement with the Issuer, at which time all unvested options to purchase common stock will be forfeited. Vested options will expire on the earlier of the one-year anniversary after Executive's continuous service on the Board of Directors terminates or ten years after the grant date. F1 · derivative.expiration_date: Options to purchase shares of common stock vest in 24 equal monthly installments of 10,000 shares each, commencing on 2/26/19 and continuing until the Reporting Person is terminated under the terms of the Reporting Person's employment agreement with the Issuer, at which time all unvested options to purchase common stock will be forfeited. Vested options will expire on the earlier of the one-year anniversary after Executive's continuous service on the Board of Directors terminates or ten years after the grant date. Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 23:45 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Option (right to buy) · Derivative | 26,342 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0000899243-19-004314 · doc4.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,342 Underlying: Common Stock · 26,342 shares Expires 2029-02-18 F1 · derivative.exercise_date: This option was granted on February 19, 2019 and is scheduled to vest in equal monthly installments through February 19, 2022, subject to continued service. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 02:14 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantStock Option (right to buy) · Derivative | 126,700 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001209191-19-000584 · doc4.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,700 Underlying: Common Stock · 126,700 shares Expires 2028-12-31 F1 · derivative.exercise_date: 126,700 options vest on 12/31/2019. Read SEC document |
| September 27, 2018 Filed Oct 1, 2018 20:21 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001209191-18-052746 · doc4.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-09-27 F1 · derivative.exercise_date: One-twelfth of the shares vest on December 27, 2018, and one twelfth vest quarterly thereafter, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 20:14 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001209191-18-051784 · doc4.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-09-18 F1 · derivative.exercise_date: 25,000 shares shall vest on each of 9/18/2019 and 9/18/2020. Read SEC document |
| May 23, 2018 Filed May 25, 2018 20:18 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 10,100 | $0.00 Strike: $38.32 | $0.00 |
DisclosureSEC source: 0001179110-18-007562 · edgar.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,100 Underlying: Common Stock · 10,100 shares Expires 2028-05-23 F1 · derivative.exercise_date: The options vest in full on the earlier of (i) May 23, 2019 and (ii) the Issuer's next annual meeting of stockholders following May 23, 2018. Read SEC document |
| January 03, 2018 Filed Jan 6, 2018 00:47 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $46.35 | $0.00 |
DisclosureSEC source: 0001209191-18-002576 · doc4.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-01-03 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 14, 2017 Filed Jun 17, 2017 00:01 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $44.20 | $0.00 |
DisclosureSEC source: 0001209191-17-040677 · doc4.xml · derivative · entry 3 Braunstein Scott · CIK 0001643875 · SVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2027-06-14 F3 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 14, 2017 Filed Jun 17, 2017 00:01 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040677 · doc4.xml · nonDerivative · entry 1 Braunstein Scott · CIK 0001643875 · SVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,982 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2018, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 05, 2017 Filed Jun 7, 2017 22:57 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 768 | $43.32 | $33,270.53 |
DisclosureSEC source: 0001209191-17-038416 · doc4.xml · nonDerivative · entry 1 Braunstein Scott · CIK 0001643875 · SVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,982 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| June 02, 2017 Filed Jun 17, 2017 00:01 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $44.10 | $0.00 |
DisclosureSEC source: 0001209191-17-040677 · doc4.xml · derivative · entry 2 Braunstein Scott · CIK 0001643875 · SVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-02 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on May 29, 2018, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 10:49 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $38.96 | $0.00 |
DisclosureSEC source: 0001179110-17-006061 · edgar.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2027-04-17 F1 · derivative.exercise_date: The options vest in full on the earlier of (i) April 17, 2018 and (ii) the Issuer's next annual meeting of stockholders following April 17, 2017. Read SEC document |
| December 07, 2016 Filed Dec 10, 2016 01:22 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $32.35 | $0.00 |
DisclosureSEC source: 0001209191-16-154554 · doc4.xml · derivative · entry 1 Braunstein Scott · CIK 0001643875 · SVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-12-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.